Our mission
To advance the next generation of immunotherapies that lead T cells to gain control over disease and improve patients’ lives.
Barinthus Biotherapeutics plc (formerly Vaccitech plc) is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
OUR APPROACH
Helping patients and their families is the guiding principle at the heart of Barinthus Biotherapeutics.
The company stands apart through its broad pipeline, built around four proprietary platform technologies; ChAdOx, MVA, SNAP-TI and SNAP-CI. These platforms are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance.